---
document_datetime: 2025-09-16 16:14:17
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tevimbra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tevimbra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.1782655
conversion_datetime: 2025-12-28 13:24:13.465685
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tevimbra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                        |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------|
| II/0018              | Extension of indication for Tevimbra in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable NSCLC based on interim results from study BGB-A317-315. | 24/07/2025                          | 21/08/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'EMEA/H/C/005919-II- 18' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | Study BGB-A317-315 is a phase 3 randomized, placebo-controlled, double-blind study to compare the efficacy and safety of neoadjuvant treatment with tislelizumab plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab versus neoadjuvant treatment with placebo plus platinum-based doublet chemotherapy followed by adjuvant placebo in patients with resectable Stage II or IIIA NSCLC. As a consequence, sections 4.1, 4.2, 5.1, and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                           |            |            |                       |                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------|
| II/0017 | Extension of indication to include, in combination with gemcitabine and cisplatin, the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy or metastatic nasopharyngeal carcinoma (NPC) for TEVIMBRA based on final results from study BGB- A317-309 (study 309). Study 309 was a Phase 3 randomised, double-blind, placebo-controlled, Asia- only study that compared the efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin (GC) versus placebo combined with GC as 1L treatment for recurrent or metastatic NPC. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP has also been | 22/05/2025 | 09/07/2025 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Tevimbra EMEA/H/C/005919/II/0017' |

<div style=\"page-break-after: always\"></div>

|         | agreed. In addition, the MAH took the opportunity to introduce editorial and administrative changes to the PI as well as to update the PI in line with the Excipients Guideline. The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       |                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------|
| II/0016 | Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy based on final results from study BGB-A317-312; a phase 3, randomized, double-blind, placebo-controlled study of platinum plus etoposide with or without tislelizumab in patients with untreated extensive- stage small cell lung cancer. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to make further changes to the SmPC, Annex II and Package Leaflet (editorial and in line with the SmPC guideline). The supportive studies BGB-A317-309 and BGB- A317-315 are provided for the purpose of updating the safety data package as well as updated data (latest CSR versions with new data cut-off) from the | 27/03/2025 | 02/05/2025 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Tevimbra EMEA/H/C/005919/II/0016' |

<div style=\"page-break-after: always\"></div>

|           | Q3W) consisting of the studies 001, 102, 203, 204, 208, 209, 301, 302, and 303 and from the combination with chemotherapy pool consisting of the studies 205, 206, 304, 305, 306, 307 and 312. Version 4.0 of the RMP has also been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------|
| II/0019/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a | 10/04/2025 | n/a | biol/immunol/immunochemical |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                   | method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test   |            |            |             |                                                                                                                                          |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/136/2 02406 | Periodic Safety Update EU Single assessment - tislelizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/01/2025 | 28/03/2025 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/136/202406. |
| II/0006           | Extension of indication to include in combination with platinum and fluoropyrimidine-based chemotherapy the first-line treatment of adult patients with human epidermal growth factor receptor-2 (HER-2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumours express PD L1 with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/10/2024 | 25/11/2024 | SmPC and PL | Please refer to Scientific Discussion 'Tevimbra H-C-5919-II- 0006'.                                                                      |

<div style=\"page-break-after: always\"></div>

|         | a tumour area positivity (TAP) score ≥ 5% for TEVIMBRA, based on results from the phase 3 study BGB-A317-305 (study 305); this is a global, randomized, double-blind, placebo-controlled study at the approved registrational dosing regimen for Tevimbra (200 mg administered IV Q3W), in combination with platinum and fluoropyrimidine- based chemotherapy, in adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.5 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------|
| II/0003 | Extension of indication to include in combination with platinum-based chemotherapy the first-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express PD-L1 with a tumour area positivity (TAP) score ≥ 5%for TEVIMBRA, based on results from study BGB-A317- 306; this is a multi-regional, randomized, placebo- controlled, double-blind phase 3 study evaluating the efficacy and safety of tislelizumab in combination with chemotherapy compared to placebo in                                                                                                                                                                                                                                                                                                                                         | 17/10/2024 | 25/11/2024 | SmPC and PL | Please refer to Scientific Discussion 'Tevimbra H-C-5919-II- 0003'. |

<div style=\"page-break-after: always\"></div>

|           | chemotherapy as first-line treatment in patients with unresectable or locally advanced recurrent or metastatic OSCC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.5 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |          | combination with   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------|
| IA/0015/G | This was an application for a group of variations. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                 | 15/10/2024 | n/a        |          |                    |
| IB/0013/G | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a                                                                                                                                                                                                                                                                      | 09/10/2024 | 25/11/2024 | Annex II |                    |

<div style=\"page-break-after: always\"></div>

|                   | biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                     |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------|
| PSUSA/136/2 02312 | Periodic Safety Update EU Single assessment - tislelizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/07/2024 | n/a        |             | PRAC Recommendation - maintenance                                   |
| II/0008           | Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy for TEVIMBRA, based on results from studies BGB-A317-303, BGB- A317-304, BGB-A317-307 and BGB A317-206. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP Version 2.0 is agreed. In addition, the MAH took the opportunity to correct some figures in section 4.8 with regards to laboratory abnormalities as well as to introduce minor editorial changes to the Product Information. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 30/05/2024 | 08/07/2024 | SmPC and PL | Please refer to Scientific Discussion 'Tevimbra H-C-5919-II- 0008'. |
| IA/0012/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/06/2024 | n/a        |             |                                                                     |

<div style=\"page-break-after: always\"></div>

|         | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009 | Update of section 5.1 of the SmPC in order to update efficacy information based on the overall survival (OS) final analyses for study BGB-A317-302; this is a randomized, controlled, open-label, global phase 3 study comparing the efficacy of the anti-PD-1 antibody tislelizumab (BGB-A317) versus chemotherapy as second line treatment in patients with advanced unresectable/metastatic oesophageal squamous cell carcinoma. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                         | 20/06/2024 | 25/11/2024 | SmPC | At the time of the prespecified final analysis, BGB-A317- 302 showed a statistically significant improvement in OS for patients randomised to the tislelizumab arm as compared to the ICC arm. The stratified HR was 0.70 (95% CI: 0.57, 0.85; 1-sided p-value of 0.0001), with a median OS of 8.6 months (95% CI: 7.5, 10.4) in the tislelizumab arm compared to 6.3 months (95% CI: 5.3, 7.0) in the ICC arm. The median follow-up times by reverse Kaplan-Meier methodology were 20.8 months in the tislelizumab arm and 21.1 months in the ICC arm. An updated analysis with additional 24 months follow-up after the prespecified final analysis showed consistent efficacy results with the final analysis. The median follow- up times by reverse Kaplan-Meier methodology were 44.7 months in the tislelizumab arm and 44.0 months in the ICC arm. Efficacy and PD-L1 subgroups (Updated analysis): At the updated analysis of OS in the PD-L1 positive subgroup (PD- L1 score ≥ 10%), the stratified HR for OS was 0.54 (95% |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | CI: 0.36 to 0.79. The median survival was 10.2 months (95% CI: 8.5 to 14.5 months) and 5.1 months (95% CI: 3.8 to 8.2 months) for the tislelizumab and ICC arms, respectively. In the PD-L1 negative subgroup (PD-L1 score <10%), the stratified HR for OS was 0.86 (95% CI: 0.65 to 1.14), with median overall survival of 7.5 months (95% CI: 5.5 to 8.9 months) and 5.8 months (95% CI: 4.8 to 6.9 months) for the tislelizumab and ICC arms, respectively. For more information, please refer to the Summary of Product Characteristics.   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0011/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                        | 16/05/2024 | 08/07/2024 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0010/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 29/04/2024 | 08/07/2024 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0002     | Update of sections 4.4 and 4.8 of the SmPC in order to update an existing warning and add 'Stevens- Johnson Syndrome (SJS)' and 'Toxic epidermal necrolysis (TEN)' to the list of adverse drug reactions                                                                                                                                                | 21/03/2024 | 08/07/2024 | SmPC, Labelling and PL | Cases of severe cutaneous adverse reactions (SCARs) including erythema multiforme (EM), Stevens-Johnson Syndrome (SJS) and Toxic epidermal necrolysis (TEN), some of them with fatal outcome, have been reported in                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | patients receiving tislelizumab. Patients should be monitored for signs or symptoms of SCARs (e.g. a prodrome of fever, flu-like symptoms, mucosal lesions or progressive skin rash) and other causes should be excluded. For suspected SCAR, tislelizumab should be withheld and the patient should be referred to specialised care for assessment and treatment. If SCAR is confirmed, tislelizumab should be permanently discontinued. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0005   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                     | 16/02/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IAIN/0004 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                | 16/02/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| T/0001    | Transfer of Marketing Authorisation                                                                                                                                                                                                                               | 17/11/2023 | 19/12/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |